News Releases

2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
1
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
2
2020-07/13
Dr. Flossie Wong-Staal, a board member of UBI since 1995, passed away on Wednesday, July 8th, at the age of 73 due to pneumonia
3
2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
4
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
5
2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
6
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
7
2020-03/19
San Miguel County orders residents to shelter in place before countywide coronavirus testing
8
2020-03/19
UBI 集團科研能量將攻堅新冠肺炎病毒帶來的人類大災難
9
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
1
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
2
2020-07/13
Dr. Flossie Wong-Staal, a board member of UBI since 1995, passed away on Wednesday, July 8th, at the age of 73 due to pneumonia
3
2020-05/19
Minister of Health and Welfare led the delegation to visit United BioPharma for the COVID-19 vaccine development program
4
2020-04/27
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
5
2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
6
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
7
2020-03/19
San Miguel County orders residents to shelter in place before countywide coronavirus testing
8
2020-03/19
UBI 集團科研能量將攻堅新冠肺炎病毒帶來的人類大災難
9
IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA) 2015-11/15
United BioPharma received approval for UB-421 Phase II clinical trial for HAART substitution treatment in treatment stabilized HIV patients from Taiwan Food and Drug Administration (TFDA) 2015-06/15
Filed an IND submission of a phase II clinical trial for HAART substitution therapy in treatment stabilized HIV patients with Taiwan Food and Drug Administration (TFDA) 2015-02/15
UB-421 product received Gold Medal award for 2014 Pharmaceutical Technology Research and Development jointly given by Ministry of Economic Affairs and Minitry of Health, Taiwan 2014-12/15
Filed an IND submission of a phase I clinical trial for UB-621, an anti-HSV-gD antibody, with Taiwan Food and Drug Administration (TFDA) 2014-12/15
United BioPharma Licenses Innovative Antibody Drug 8D6 for Asthma and Allergy Treatment from Academia Sinica 2014-12/14
Completion of phase IIa clinical trial of UB-421, the anti-CD4 antibody for treatment in HIV treatment naïve patients 2014-11/15
United BioPharma was selected as the recipient by government’s Industrial Cooperation Program (ICP) to carry out the technology transfer of Single Use Disposal system in biological manufacturing from GE Healthcare 2014-09/15
anti-CD4 mAb drug candidate UB-421 won the Gold Medal Prize for Innovative Research and Development given by Taipei City government for 2014 Taipei Biotechnology Award 2014-09/15
United BioPharma was listed on the Taiwan Emerging Stock Market (Stock code : 6471) 2014-09/13
United BioPharma, Inc. Copyright (c) 2020